Download Prostate Cancer Management Pdf

A one-page (front and back) introduction of a specific type of cancer or cancer-related topic, including an overview of the subject, words to know, and questions to ask the health care team. Browse titles and download as printable PDFs.

Download prostate cancer Management pdf

Comprehensive, patient-friendly guides that contain trusted information about the diagnosis, treatment, side effects, and psychosocial effects of a specific cancer. Five titles are available to download as a PDF in English or Spanish here:

96.6% of males survive prostate cancer for at least one year, this falls to 86.6% surviving for five years or more, as shown by age-standardised net survival for patients diagnosed with prostate cancer during 2013-2017 in England.[1]

Prostate cancer survival continues to fall beyond five years after diagnosis. 77.6% of males are predicted to survive their disease for ten years or more, as shown by age-standardised net survival for patients diagnosed with prostate cancer during 2013-2017 in England.[1]

Five-year survival for prostate cancer shows an unusual pattern with age: survival gradually increases from 91% in men aged 15-49 and peaks at 94% in 60-69 year olds; survival falls thereafter, reaching its lowest point of 66% in 80-99 year olds patients diagnosed with prostate cancer in England during 2009-2013.[1] The higher survival in men in their sixties is likely to be associated with higher rates of PSA testing in this age group.

As with most cancers, survival for prostate cancer is improving. However, interpretation of prostate cancer survival trends is difficult as the case-mix on which they are based is likely to have changed over time with earlier diagnoses following the advent of TURP and PSA testing. The detection of a greater proportion of latent, earlier, slow-growing tumours in more recent time periods will have the effect of raising survival rates due to lead-time bias (that is, the difference in time between screen detection and clinical detection in the absence of screening).[1] Lead-time bias for prostate cancer is estimated to be between five and 12 years, varying with a man's age at screening.[2,3] Data from the European Randomized Study of Prostate Cancer estimates that for a single screening test, mean lead times are 12 years at age 55 and six years at age 75.[3] Some of the increase may also be attributed to genuine improvements in survival due to more effective treatment, for both early, aggressive prostate cancers and advanced cases.[4]

One-year net survival for prostate cancer is highest for patients diagnosed at Stage 1, Stage 2, and lowest for those diagnosed at Stage 4, as 2013-2017 data for England show.[1] 100% of patients diagnosed at Stage 1, Stage 2 survived their disease for at least one year, compared to 88% of patients diagnosed at Stage 4.[1]

One year net survival for unknown or missing stage is 94%, while one year survival for unstageable cancer is 42%. Lack of staging information may in some cases reflect advanced stage at diagnosis as very unwell patients may not undergo staging tests if the invasiveness of the testing outweighs the potential benefit of obtaining stage information. Incomplete staging assessment may also be associated with socio-demographic and clinical characteristics of the patient [2]. Stage completeness for prostate cancer was 88% in 2013-2017 [1].

Five-year relative survival for prostate cancer in men in England (80%) is below the average for Europe (83%). Wales (78%), Scotland (79%) are also below the European average but Northern Ireland (83%) is similar to the European average.[1] Across the European countries for which data is available, five-year relative survival in men ranges from 51% (Bulgaria) to 90% (Austria).[1]

A table of NHS England interim treatment regimens gives possible alternative treatment options for use during the COVID-19 pandemic to reduce infection risk. This may affect decisions for patients with prostate cancer. See the COVID-19 rapid guideline: delivery of systemic anticancer treatments for more details.

September is Prostate Cancer Awareness Month. According to the American Cancer Society, prostate cancer is the second most common cancer among men, and approximately one man in eight will be diagnosed with prostate cancer during his lifetime. Prostate cancer is a serious disease, but it is not fatal for most men who are diagnosed with it. 041b061a72